SBIR Phase I: Safety Syringe Needle for Prevention of Unintended/Accidental Puncture (Needlestick Injury)

Gnu Company, Llc, Winchester MA

Investigators

Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel medical device for intramuscular injections that will reduce needlestick injury. Unintended or accidental puncture is the second most common occupational hazard for healthcare staff. An estimated 385,000 needlestick injuries occur in the United States each year impacting 5.6 million healthcare workers. Needlestick injury represents one of the largest risks, both financially ($258 million annually) and medically (e.g., bloodborne pathogen exposure), to healthcare providers. This project aims to develop a novel, flexible hypodermic needle with a safety syringe that enables rapid injections while replacing sharp needles and significantly reducing risks of unintended health care provider injury. This Small Business Innovation Research Phase I project provides a novel, flexible, polymer needle-based safety syringe for health care providers to perform intramuscular injections in patients. A novel and variable stiffness shaft is integrated with an external safety lumen mechanism to create an integrated delivery system with the same delivery reliability and repeatability as standard needlesticks. The design will be prototyped and evaluated under a variety of human factors considerations. The device will be required to pass several mechanical tests for puncture, insertion, and lumen integrity in a consistent manner, as anticipated during routine clinical use. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.